Ignite Creation Date:
2024-05-06 @ 12:23 AM
Last Modification Date:
2024-10-26 @ 10:49 AM
Study NCT ID:
NCT01569334
Status:
UNKNOWN
Last Update Posted:
2014-08-29
First Post:
2011-02-14
Brief Title:
Identification of Non Invasive Biomarkers of Immune Endothelial Injury and Repair Associated With Cardiac Allograft Vasculopathy
Sponsor:
Assistance Publique Hopitaux De Marseille
Organization:
Assistance Publique Hopitaux De Marseille
Study Overview
Official Title:
Identification of Non Invasive Biomarkers of Immune Endothelial Injury and Repair Associated With Cardiac Allograft Vasculopathy
Status:
UNKNOWN
Status Verified Date:
2014-08
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Heart transplantation is the best option for patients with end-stage heart failure Cardiac allograft vasculopathy CAV is the leading cause of death following cardiac transplantation and is not managed by current therapies Its pathogenesis traduces in an accelerated form of coronary artery disease CAD with similarities to atherosclerosis but also particular features of endothelial dysfunction associated to the alloimmune conflict and humoral responses toward the graft Intravascular ultrasound IVUS is the validated invasive method for late CAV diagnosis but occurs lesions are established Identification of reliable non-invasive early endothelial injury biomarkers that reflect mechanisms of cardiac damage thus remain a major challenge to optimize therapeutic management of post transplant morbidity Endothelial dysfunction is a central feature of both CAV and CAD and results from a desquilibrium in the balance of endothelial lesion and repair that is partly controlled by recipient immune system Through their expression of receptors sensing antibodies FcR CD16 and endothelial stress-induced signals CX3CR1 fractalkine receptor and NKG2D MICA receptors Natural Killer NK cells represent effector cells with unique potential to generate both humoral and innate immune injury of graft endothelium
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2010 18 | OTHER | AP HM | None |